Cantor Fitzgerald Trims Humana (NYSE:HUM) Target Price to $360.00

Humana (NYSE:HUM) had its target price cut by equities research analysts at Cantor Fitzgerald from $391.00 to $360.00 in a research report issued on Thursday, Benzinga reports. The firm currently has a “neutral” rating on the insurance provider’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 17.68% from the company’s previous close. Cantor Fitzgerald also issued estimates for Humana’s FY2024 earnings at $16.04 EPS.

HUM has been the topic of a number of other research reports. Raymond James began coverage on shares of Humana in a research report on Friday, March 22nd. They issued a “market perform” rating on the stock. Deutsche Bank Aktiengesellschaft lowered shares of Humana from a “buy” rating to a “hold” rating and cut their target price for the company from $595.00 to $360.00 in a research report on Thursday, January 25th. Mizuho cut their target price on shares of Humana from $550.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, January 26th. Argus lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, March 13th. Finally, Jefferies Financial Group cut their target price on shares of Humana from $411.00 to $381.00 and set a “buy” rating on the stock in a research report on Monday, April 22nd. Eleven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $433.74.

Humana Stock Performance

NYSE HUM opened at $305.91 on Thursday. The company has a current ratio of 1.67, a quick ratio of 1.59 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $36.86 billion, a price-to-earnings ratio of 19.05, a P/E/G ratio of 1.82 and a beta of 0.45. The firm’s 50 day simple moving average is $327.77 and its 200 day simple moving average is $394.49. Humana has a 1 year low of $299.23 and a 1 year high of $541.21.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.12 by $1.11. The business had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. The firm’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same quarter last year, the business posted $9.38 EPS. As a group, research analysts expect that Humana will post 16.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Jorge S. Mesquita bought 545 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was acquired at an average price of $367.09 per share, with a total value of $200,064.05. Following the completion of the purchase, the director now directly owns 2,578 shares of the company’s stock, valued at $946,358.02. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.32% of the stock is owned by insiders.

Hedge Funds Weigh In On Humana

Hedge funds have recently bought and sold shares of the company. Exchange Traded Concepts LLC increased its stake in Humana by 103.0% in the third quarter. Exchange Traded Concepts LLC now owns 2,883 shares of the insurance provider’s stock valued at $1,403,000 after purchasing an additional 1,463 shares in the last quarter. Caprock Group LLC grew its holdings in shares of Humana by 3.6% during the third quarter. Caprock Group LLC now owns 1,421 shares of the insurance provider’s stock valued at $693,000 after buying an additional 50 shares during the last quarter. UMB Bank n.a. grew its holdings in shares of Humana by 2.8% during the third quarter. UMB Bank n.a. now owns 805 shares of the insurance provider’s stock valued at $392,000 after buying an additional 22 shares during the last quarter. Czech National Bank grew its holdings in shares of Humana by 46.4% during the third quarter. Czech National Bank now owns 21,656 shares of the insurance provider’s stock valued at $10,536,000 after buying an additional 6,866 shares during the last quarter. Finally, Aaron Wealth Advisors LLC acquired a new position in shares of Humana during the third quarter valued at about $213,000. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.